Here are three highlights from the first quarter:
1. Data from Ironwood’s investigational gastric retentive bile acid sequestrant demonstrated improvements in relief of heartburn and other symptoms.
2. Ironwood reported continued activity with a Phase IIa clinical study evaluating the ability of guanylate cyclase-C agonist to provide diabetic gastroparesis symptom relief.
3. Dosing began in a Phase I clinical study of he first clinical compound in a broad library of sGC stimulators for the potential treatment of cardiovascular disease.
More articles on GI/endoscopy:
UMass Memorial Medical Group adds Dr. Kerri Gosselin — 3 quick facts
Tissue-engineered small intestine successful — Is a new short bowel syndrome treatment next? 3 things to know
Cahaba GBA to cover EndoGastric Solutions’ TIF procedure: 4 important takeaways
